3-(6-alkoxy-5-chlorobenzo[D]isoxazol-3-YL)propanoic acid useful as kynurenine monooxygenase inhibitors

US10273232B2 · kind B2 · utility

Assignee

• GlaxoSmithKline Intellectual Property Development Limited · GB

Inventors

• Anne Marie Jeanne Bouillot · Les Ulis, FR
• Alexis Denis · Paris, FR
• John Liddle · Stevenage, GB
• Ann Louise Walker · Stevenage, GB

Key dates

• Filing date: Feb 20, 2018
• Grant date: Apr 30, 2019
• Expiry date: Feb 20, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a compound of formula (I) or pharmaceutically acceptable salts thereof, which are Kynurenine monooxygenase (KMO) inhibitors, which are useful in the treatment of various disorders, which may include, but are not limited to, for diseases such as, for example: acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.